Cerebrolysin – Neurotrophic Peptide Bioregulator for Research Use Only

Category: Neuroregeneration & Cognitive Function Bioregulators

SKU: Cerebrolysin-30MG | Form: Lyophilized Powder | Purity: ≥ 99% (HPLC Tested)

For Research Use Only – Not for Human Consumption

Product Overview

Cerebrolysin is a peptide-based neurotrophic bioregulator composed of low–molecular weight neuropeptides and free amino acids derived from porcine brain proteins. It is widely studied in neuroscience research for its ability to mimic endogenous neurotrophic factors and support neuronal survival, plasticity, and repair.

In laboratory and clinical research settings, Cerebrolysin is used to investigate mechanisms involved in neuroprotection, synaptic remodeling, and functional recovery following neurological injury or degeneration.

Cerebrolysin Research Summary

Extensive preclinical and clinical research indicates that Cerebrolysin exerts neuroprotective and neurorestorative effects through multimodal mechanisms that resemble naturally occurring growth factors.

Key findings include:

• Neuroprotection: Reduces neuronal apoptosis and excitotoxic damage in injury models.
• Neuroplasticity Enhancement: Supports synaptic remodeling and dendritic growth.
• Neurogenesis Support: Promotes survival and differentiation of neuronal progenitor cells.
• Anti-Inflammatory Effects: Modulates microglial activation and neuroinflammatory signaling.
• Mitochondrial Support: Improves cellular energy metabolism in neurons under stress.

Cerebrolysin has been shown to interact with pathways associated with BDNF, NGF, and GDNF activity, making it a valuable research compound in neurodegenerative and recovery-focused investigations.

Cognitive & Neurological Research Applications

• Neurodegenerative Disease Models (Alzheimer’s, Parkinson’s)
• Stroke & Traumatic Brain Injury Recovery Research
• Cognitive Decline & Memory Function Studies
• Synaptic Plasticity & Learning Mechanism Analysis
• Neuroinflammation & Oxidative Stress Research

Neurorepair & Functional Recovery Research

Cerebrolysin is extensively evaluated in models of neurological recovery due to its capacity to support functional reorganization of neural networks following injury.

Research observations include improved motor coordination, enhanced cognitive performance, and accelerated recovery timelines in controlled laboratory and clinical studies.

For Research Use Only

This material is supplied strictly for laboratory and research purposes only. It is not approved for human or veterinary administration, diagnostic use, or consumption. All handling must comply with institutional and regulatory research guidelines.

References

• Masliah E. et al. Neuroprotective Effects of Cerebrolysin in Experimental Models of Neurodegeneration. Journal of Neural Transmission, 1999.

• Plosker GL, Gauthier S. Cerebrolysin: A Review of its Use in Dementia. CNS Drugs, 2009.

• Zhang C. et al. Cerebrolysin Attenuates Neuronal Apoptosis and Oxidative Stress After Ischemic Injury. Stroke, 2010.

• Hartbauer M. et al. Protection of Neurons from Excitotoxic Cell Death by Cerebrolysin. Journal of Neural Transmission, 2001.

• Alvarez XA. et al. Synaptic and Dendritic Remodeling Induced by Cerebrolysin. Neurobiology of Aging, 2006.

• Chen H. et al. Modulation of BDNF and NGF Signaling by Cerebrolysin in Neuronal Cultures. Journal of Neuroscience Research, 2007.

• Feng Y. et al. Anti-Inflammatory and Microglial Modulatory Effects of Cerebrolysin. Neuroimmunology and Neuroinflammation, 2014.

• Bastianetto S. et al. Cerebrolysin Improves Mitochondrial Function and Reduces Oxidative Stress. Neuroscience, 2000.

• Heiss WD. et al. Cerebrolysin in Acute Ischemic Stroke: Functional and Cognitive Outcomes. Stroke, 2012.

• Muresanu DF. et al. Neurorecovery Effects of Cerebrolysin in Traumatic Brain Injury. Journal of Medicine and Life, 2016.

• Rüther E. et al. Efficacy of Cerebrolysin in Alzheimer’s Disease. International Clinical Psychopharmacology, 2001.

Alvarez XA. et al. Reduction of Amyloid Pathology and Cognitive Decline with Cerebrolysin. Journal of Neural Transmission, 2011.